About: Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 October 1994

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 1994 (uk) article scientifique publié en 1994 (fr) im Oktober 1994 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'ochobre de 1994 (ast) scientific article published on 01 October 1994 (en)
publication date	wds:Q72486191-3709CE53-3F0A-4FC2-B10F-479D73E3457C
publication date	1994-10-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q72486191-173955C0-4BDC-4EF8-821D-7636F870091D wds:Q72486191-24B40D5B-FF92-4FD7-82B6-AEBC1D23257D wds:Q72486191-2AAEC392-D420-435A-81DF-82BE89FE0111 wds:Q72486191-3173D635-4C87-4476-8704-B1EC05EA065C wds:Q72486191-569B9890-F23C-4D4D-95F1-F9636012B191 wds:Q72486191-76DABC88-1500-443E-9691-EBDFDCDB4EE8 wds:Q72486191-7CCACA58-14C8-49C6-A078-0F63134FD2DA wds:Q72486191-98D7CE62-85C4-4027-84B3-FBBCEB3E2284 wds:Q72486191-AD630DDA-0FC6-4528-B2A3-3ABC08A2E9BA wds:Q72486191-D0CF83F6-517A-4B5E-B92E-7F250D671AFD
author name string	Wang GJ Fowler JS Logan J Volkow ND Alexoff D Pappas N Wolf AP MacGregor RR Shea C Schyler D
rdfs:label	Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal (en) Slow recovery of human brain MAO B after L-deprenyl (nl)
skos:prefLabel	Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal (en) Slow recovery of human brain MAO B after L-deprenyl (nl)
name	Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal (en) Slow recovery of human brain MAO B after L-deprenyl (nl)
title	wds:Q72486191-E19C1FF2-2383-484A-A9F2-D1CCBD02EA12
title	Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal (en)
page(s)	wds:Q72486191-D3CF12A3-683D-4159-B331-4A3F98DC86AD
page(s)	86-93
instance of	wds:Q72486191-095C4BAD-AF83-4AD0-B663-62418C8A60AE
instance of	scholarly article
PubMed ID	wds:Q72486191-98A0E356-EA66-4619-B233-E7DF57F11814
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7839316
PubMed ID	7839316
published in	wds:Q72486191-14AE3C3C-E236-4DA7-BA8D-1511987F25B5
published in	Synapse
issue	wds:Q72486191-4D1B14D8-7FAB-41A8-BA33-8CF7A41EE4A4
volume	wds:Q72486191-CB5FE573-DF2C-497B-B64F-1C3B9DA3170D
issue	2
volume	18
DOI	wds:Q72486191-BCE2F04A-D250-412D-B6AA-DDC6B19BD14E
DOI	http://dx.doi.org/10.1002/SYN.890180203
DOI	10.1002/SYN.890180203
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q72486191
is cites work of	Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Functional brain imaging of tobacco use and dependence Monoamine oxidase and cigarette smoking. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease A review of graphical methods for tracer studies and strategies to reduce bias A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease Inhibition of monoamine oxidase B in the brains of smokers Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal Monoamine oxidase and catechol-O-methyltransferase inhibitors Current status of symptomatic medical therapy in Parkinson's disease A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B. Flavonoids from Sideritis Species: Human Monoamine Oxidase (hMAO) Inhibitory Activities, Molecular Docking Studies and Crystal Structure of Xanthomicrol. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. In vivo brain imaging of human exposure to nicotine and tobacco Translational neuroimaging: positron emission tomography studies of monoamine oxidase. A Review of Sleep and Its Disorders in Patients with Parkinson's Disease in Relation to Various Brain Structures Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects? MAO-inhibitors in Parkinson's Disease Pharmacokinetic optimisation in the treatment of Parkinson's disease Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells Slow onset of CNS drugs: can changes in protein concentration account for the delay? Is the onset of psychoactive drug effects compatible with a protein-synthesis mechanism? Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([(18)F]-AV-1451) Binding. Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease Molecular imaging of movement disorders Parkinson's disease: medical and surgical treatment Species differences in [11C]clorgyline binding in brain. An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo. Rasagiline in treatment of Parkinson's disease. Rasagiline: a review of its use in the management of Parkinson's disease Synthesis and in vivo studies of a specific monoamine oxidase B inhibitor: 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)- 1,3,4-oxadiazol-[11C]-2(3H)-one. Selegiline in Patients With Disorder of Consciousness: An Open Pilot Study In Vivo Metabolic Trapping Radiotracers for Imaging Monoamine Oxidase-A and -B Enzymatic Activity.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software